In a study of glucagon-like peptide receptor-1 agonists — which include Ozempic, Wegovy, Mounjaro and about a dozen other drugs approved for diabetes or chronic weight management — researchers found the medications suppressed heart inflammation in mice.
The results lend clues to other possible treatment avenues for GLP-1s, including heart disease, kidney disease, Alzheimer’s disease and Parkinson’s disease.
“The anti-inflammatory actions of GLP-1 are likely in part organized through a subset of brain neurons,” Daniel Drucker, MD, the study’s lead author, who works at Mount Sinai Hospital-Toronto, told Bloomberg.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
